MSD to signal licensing pacts with 5 Indian drug companies for oral drug candidate for Covid-19, Well being Information, ET HealthWorld

0
19


MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for Covid-19Drug agency MSD has determined to enter into voluntary licensing agreements for investigational oral antiviral drug candidate ‘molnupiravir‘, which is being studied for the therapy of Covid-19, with Indian drug firms Solar Pharma, Cipla, Dr Reddy’s, Emcure Pharma and Hetero Labs, its Indian arm stated on Tuesday. Molnupiravir is an investigational oral antiviral agent, at present being studied in a Part 3 trial for the therapy of non-hospitalised sufferers with confirmed Covid-19, MSD India stated in an announcement.

MSD India is an entirely owned subsidiary of Merck Sharp & Dohme (MSD) and generally known as Merck & Co., Inc, in the USA and Canada.

MSD has determined to enter into non-exclusive voluntary licensing agreements for molnupiravir with 5 established Indian generic producers — Cipla, Dr Reddy’s Laboratories, Emcure Prescription drugs, Hetero Labs and Solar Pharmaceutical Industries, it added.

These 5 producers have World Well being Group (WHO) Pre-Certified Manufacturing amenities and expertise as main suppliers to international and key low- and middle-income international locations (LMICs) procurers, MSD India stated.

MSD has entered into these agreements to speed up availability of molnupiravir in India and in different LMICs following approvals or emergency authorisation by native regulatory companies, it added.

“These agreements, towards which we have now been working as we have now been learning molnupiravir, will assist to speed up entry to molnupiravir in India and world wide,” Merck & Co, Inc, US Chairman and CEO Kenneth C Frazier stated.

“We stay dedicated to aiding within the international response that may convey aid to the folks of India and, in the end, convey an finish to the pandemic,” he added.

Underneath the agreements, Merck & Co, Inc, US will present licences to those producers to produce molnupiravir to India and greater than 100 LMICs. The corporate can also be in discussions with the Medicines Patent Pool to discover the potential for extra licenses, the assertion stated.

“By partnerships with established Indian generics producers, we’re reinforcing our dedication in direction of increasing entry to molnupiravir in India,” MSD-India Area MD Rehan A Khan stated.

Merck & Co, Inc may even donate greater than USD 5 million value of oxygen-production gear, masks, hand sanitiser and monetary support to assist aid efforts in India, the assertion stated.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here